

JAN 27 2000

**510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
For Abbott Aeroset Carbamazepine Assay**

1. Manufacturer and Contact Information:

Manufacturer: Syva Company
3403 Yerba Buena Rd.
P.O. Box 49013
San Jose, CA 95161-9013

Abbott Laboratories
820 Mission Street
South Pasadena, CA 91030

Distributor: Abbott Laboratories
K-Complex
Route 41 & Martin Luther King Drive
North Chicago, IL 60064

Contact Information: Paul Rogers
Syva Company
3403 Yerba Buena Road
San Jose, CA 95161-9013
Tel: 408-239-2000

2. Device Classification Name:

The Clinical Chemistry and Clinical Toxicology Devices Panel have classified "Carbamazepine Test System" as Class II.

3. Intended Use:

Abbott Aeroset[®] Carbamazepine Assay is a homogeneous enzyme immunoassay. The assay is intended for use in the quantitative analysis of carbamazepine in human serum or plasma.

4. Device Description and Characteristics:

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of SMDA 1990.

Syva Company is submitting the Premarket Notification, 510(k) on behalf of Abbott Laboratories to convey Abbott's intention to commercially market an *in vitro* diagnostic reagent test kit for the analysis of carbamazepine in human serum or plasma. The Abbott Aeroset[®] Carbamazepine Assay is a homogenous enzyme assay intended for use in quantitative analysis of carbamazepine in human serum or plasma. The Abbott Aeroset[®] Carbamazepine Assay and calibrators has been found to be equivalent to the predicate device: Emit[®] 2000 Carbamazepine Assay (K913066) with regard to intended use, assay sample, and overall performance characteristics.

**510(k) SUMMARY OF SAFETY AND EFFECTIVENESS
For Abbott Aeroset Carbamazepine Assay (cont.)**

Comparative Analysis: The Abbott Aeroset® Carbamazepine Assay and calibrators showed excellent correlation to the predicate method. The comparative analysis to the predicate method resulted in a correlation of 0.99 with a slope value of 1.06.

Precision: A Precision study was performed and the Abbott Aeroset® Carbamazepine Assay demonstrated acceptable within-run precision with coefficients of variation (%CV) ranging from 1.42% to 2.88% and acceptable total precision with coefficients of variation (%CV) ranging from 2.74% to 3.28%.

5. Substantial Equivalence:

In conclusion, Abbott Laboratories considers the Abbott Aeroset® Carbamazepine Assay and Abbott Aeroset® Carbamazepine Calibrators to be substantially equivalent to the Emit® 2000 Carbamazepine Assay(K913066) and Emit® 2000 Carbamazepine Calibrators(K913066) with regard to intended use, assay sample, and overall performance characteristics.



Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

NOV 15 2007

Abbott Laboratories
C/O Mary Beth Fennel
Syva Company Regulatory Affairs
3403 Yerba Buena Road
P.O. Box 49013
San Jose, CA 95161-9013

Re: k993028

Trade/Device Name: Abbot Aeroset Carbamazepine Assay
Abbot Aeroset Carbamazepine Calibrators
Regulation Number: 21 CFR 862.3645
Regulation Name: Neuroleptic drugs radioreceptor assay test system.
Regulatory Class: II
Product Code: KLT, DLJ
Dated: January 10, 2000
Received: January 11, 2000

Dear Ms. Fennel:

This letter corrects our substantially equivalent letter of January 27, 2000.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not

limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

You may obtain general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink that reads "Carol Benson". The signature is written in a cursive style with a large, looped initial "C".

Jean M. Cooper, M.S. D.V.M.
Director
Division of Chemistry and Toxicology
Office of In Vitro Diagnostic Device Evaluation and
Safety
Center for Devices and
Radiological Health

Enclosure: Indications for Use Statement

510(k) Number (If known): K993028

Device Name: Abbott Aeroset® Carbamazepine Assay
Abbott Aeroset® Carbamazepine Calibrators

Indications for Use:

The Abbott Aeroset® Carbamazepine Assay is a homogeneous enzyme immunoassay intended for use in the quantitative analysis of carbamazepine in human serum or plasma on the Abbott Aeroset® analyzer (K980367). Monitoring serum carbamazepine concentrations, along with careful clinical assessment, is the most effective means of improving seizure control, reducing the risk of toxicity, and minimizing the need for additional anticonvulsant medication for the following reasons (1, 2):

- Serum carbamazepine concentrations correlate better with pharmacologic activity than does dosage.
- Changes in carbamazepine's half-life with prolonged treatment and interindividual differences in carbamazepine metabolism make it difficult to predict serum levels from the administered dosage, particularly during concomitant therapy with other anticonvulsants. Serum level monitoring helps physicians individualize dosage regimens.
- Carbamazepine is safe and effective only in a narrow range of serum concentrations. Carbamazepine-10,11-epoxide, a major metabolite of carbamazepine, is pharmacologically active and found in plasma and tissues (3).

Methods historically used to monitor serum carbamazepine concentrations include gas-liquid chromatography, high-performance liquid chromatography, and immunoassay (1,2,4,5).

Continued on next page

Jean Cozart
 (Division Sign-Off)
 Division of Clinical Laboratories
 510(k) Number: K993028

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

 Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use _____
 (Per 21 CFR 801.109) (Optional Format 1-2-96)